{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:33:49Z","timestamp":1794584029002,"version":"4.9.1"},"reference-count":241,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":52,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.neurot.2024.e00443","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T14:07:25Z","timestamp":1726236445000},"page":"e00443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials"],"prefix":"10.1016","volume":"21","author":[{"given":"Jasna","family":"Metovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yedda","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Eichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2024.e00443_bib1","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1212\/WNL.0b013e3181eee46b","article-title":"The burden of inherited leukodystrophies in children(e\u2013Pub ahead of print)(CME)","volume":"75","author":"Bonkowsky","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00443_bib2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00401-017-1739-1","article-title":"Leukodystrophies: a proposed classification system based on pathological changes and pathogenetic mechanisms","volume":"134","author":"van der Knaap","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2024.e00443_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.902261","article-title":"Emerging cellular themes in leukodystrophies","volume":"10","author":"Nowacki","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.neurot.2024.e00443_bib4","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.3390\/pharmaceutics15112522","article-title":"Gene and cellular therapies for leukodystrophies","volume":"15","author":"Aerts-Kaya","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neurot.2024.e00443_bib5","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1474-4422(19)30143-7","article-title":"Diagnosis, prognosis, and treatment of leukodystrophies","volume":"18","author":"van der Knaap","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1219324","article-title":"Adult-onset leukodystrophies: a practical guide, recent treatment updates, and future directions","volume":"14","author":"Muthusamy","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12987-022-00316-0","article-title":"The neurovascular unit in leukodystrophies: towards solving the puzzle","volume":"19","author":"Zarekiani","year":"2022","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.neurot.2024.e00443_bib8","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.3390\/pharmaceutics13111779","article-title":"Blood-brain barrier dysfunction in CNS disorders and putative therapeutic targets: an overview","volume":"13","author":"Archie","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neurot.2024.e00443_bib9","first-page":"99","article-title":"Chapter 4 - ex vivo gene therapy for the treatment of neurological disorders","volume":"vol. 230","author":"Gowing","year":"2017"},{"key":"10.1016\/j.neurot.2024.e00443_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s42466-020-00075-z","article-title":"Gene specific therapies \u2013 the next therapeutic milestone in neurology","volume":"2","author":"Brenner","year":"2020","journal-title":"Neurol Res Pract"},{"key":"10.1016\/j.neurot.2024.e00443_bib11","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.neurot.2024.e00443_bib12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13023-015-0313-y","article-title":"Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report","volume":"10","author":"Boucher","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.neurot.2024.e00443_bib13","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbmt.2013.01.010","article-title":"Neurodevelopmental outcomes of umbilical cord blood transplantation in metachromatic leukodystrophy","volume":"19","author":"Martin","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.neurot.2024.e00443_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/bloodadvances.2017010645","article-title":"Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies","volume":"2","author":"van den Broek","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.neurot.2024.e00443_bib15","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0140-6736(00)02629-5","article-title":"Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy","volume":"356","author":"Shapiro","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2024.e00443_bib16","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1182\/blood-2003-10-3402","article-title":"Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999","volume":"104","author":"Peters","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.neurot.2024.e00443_bib17","doi-asserted-by":"crossref","first-page":"fcz048","DOI":"10.1093\/braincomms\/fcz048","article-title":"Clinical efficacy of haematopoietic stem cell transplantation for adult adrenoleukodystrophy","volume":"2","author":"Matsukawa","year":"2020","journal-title":"Brain Commun"},{"key":"10.1016\/j.neurot.2024.e00443_bib18","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa042604","article-title":"Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease","volume":"352","author":"Escolar","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00443_bib19","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1182\/blood.2020005477","article-title":"Long-term neurodevelopmental outcomes of hematopoietic stem cell transplantation for late-infantile Krabbe disease","volume":"137","author":"Yoon","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.neurot.2024.e00443_bib20","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1212\/WNL.0000000000004418","article-title":"Developmental outcomes of cord blood transplantation for Krabbe disease: a 15-year study","volume":"89","author":"Wright","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00443_bib23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-0033-1364179","article-title":"Hematopoietic stem cell transplantation in the leukodystrophies: a systematic review of the literature","volume":"45","author":"Musolino","year":"2014","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.neurot.2024.e00443_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/acn3.50975","article-title":"Metachromatic leukodystrophy and transplantation: remyelination, no cross-correction","volume":"7","author":"Wolf","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.895511","article-title":"Hematopoietic stem cell transplantation for neurological disorders: a focus on inborn errors of metabolism","volume":"16","author":"de Vasconcelos","year":"2022","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.neurot.2024.e00443_bib24","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s13023-023-02814-2","article-title":"A\u00a0systematic review of clinical effectiveness and safety for historical and current treatment options for metachromatic leukodystrophy in children, including atidarsagene autotemcel","volume":"18","author":"Armstrong","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.neurot.2024.e00443_bib25","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2009-12-256461","article-title":"The galactocerebrosidase enzyme contributes to the maintenance of a functional hematopoietic stem cell niche","volume":"116","author":"Visigalli","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.neurot.2024.e00443_bib26","doi-asserted-by":"crossref","first-page":"58ra84","DOI":"10.1126\/scitranslmed.3001522","article-title":"Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy","volume":"2","author":"Gentner","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurot.2024.e00443_bib27","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3390\/v13081526","article-title":"Designing lentiviral vectors for gene therapy of genetic diseases","volume":"13","author":"Poletti","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.neurot.2024.e00443_bib28","first-page":"5S1","article-title":"Myelodysplastic syndromes after Eli-cel gene therapy for cerebral adrenoleukodystrophy (CALD) [ASGCT abstract 11]","volume":"30","author":"Williams","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/exnr.1999.7178","article-title":"Lentiviral gene transfer to the nonhuman primate brain","volume":"160","author":"Kordower","year":"1999","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41434-020-0172-6","article-title":"Maximizing lentiviral vector gene transfer in the CNS","volume":"28","author":"Humbel","year":"2021","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib31","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1089\/hum.2018.079","article-title":"Intrathecal adeno-associated viral vector-mediated gene delivery for adrenomyeloneuropathy","volume":"30","author":"Gong","year":"2019","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.omtm.2023.06.001","article-title":"Adeno-associated virus-mediated gene therapy in a patient with Canavan disease using dual routes of administration and immune modulation","volume":"30","author":"Corti","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00443_bib33","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/mt.2013.138","article-title":"A\u00a0single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice","volume":"21","author":"Ahmed","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.omtm.2018.02.005","article-title":"Development of intrathecal AAV9 gene therapy for giant axonal neuropathy","volume":"9","author":"Bailey","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00443_bib35","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1089\/hum.2012.015","article-title":"Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice","volume":"23","author":"Piguet","year":"2012","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib36","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1089\/hum.2017.151","article-title":"AAVrh10 gene therapy ameliorates central and peripheral nervous system disease in canine globoid cell leukodystrophy (krabbe disease)","volume":"29","author":"Bradbury","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.nbd.2016.10.001","article-title":"N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase","volume":"96","author":"Francis","year":"2016","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2024.e00443_bib38","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1089\/hum.2021.245","article-title":"Efficacy and safety of a krabbe disease gene therapy","volume":"33","author":"Hordeaux","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.neurot.2024.e00443_bib40","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fnmol.2015.00036","article-title":"Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice","volume":"8","author":"Tanguy","year":"2015","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.neurot.2024.e00443_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.988914","article-title":"Routes of administration for adeno-associated viruses carrying gene therapies for brain diseases","volume":"15","author":"Zhou","year":"2022","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.neurot.2024.e00443_bib42","doi-asserted-by":"crossref","first-page":"473","DOI":"10.5114\/bta.2021.111111","article-title":"Retrograde capabilities of adeno-associated virus vectors in the central nervous system","volume":"102","author":"Surdyka","year":"2021","journal-title":"Biotechnologia"},{"key":"10.1016\/j.neurot.2024.e00443_bib43","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.bbi.2024.03.005","article-title":"Use of adeno-associated viruses for transgenic modulation of microglia structure and function: a review of technical considerations and challenges","volume":"118","author":"Ball","year":"2024","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.neurot.2024.e00443_bib44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0378-1119(91)90434-D","article-title":"Efficient selection for high-expression transfectants with a novel eukaryotic vector","volume":"108","author":"Hitoshi","year":"1991","journal-title":"Gene"},{"key":"10.1016\/j.neurot.2024.e00443_bib45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1006\/exnr.2002.7942","article-title":"Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain","volume":"176","author":"Klein","year":"2002","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0378-1119(02)00878-8","article-title":"Generation of a synthetic mammalian promoter library by modification of sequences spacing transcription factor binding sites","volume":"297","author":"Torn\u00f8e","year":"2002","journal-title":"Gene"},{"key":"10.1016\/j.neurot.2024.e00443_bib47","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1128\/JVI.00649-08","article-title":"Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle","volume":"82","author":"Penaud-Budloo","year":"2008","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.neurot.2024.e00443_bib48","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.omtm.2021.02.014","article-title":"Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec","volume":"21","author":"Day","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00443_bib49","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173510","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","volume":"134","author":"Salabarria","year":"2024","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.neurot.2024.e00443_bib50","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense oligonucleotide therapies for neurodegenerative diseases","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu Rev Neurosci"},{"key":"10.1016\/j.neurot.2024.e00443_bib51","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000517686","article-title":"Antisense oligonucleotide therapy for neurodevelopmental disorders","volume":"43","author":"Hill","year":"2021","journal-title":"Dev Neurosci"},{"key":"10.1016\/j.neurot.2024.e00443_bib52","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1021\/bi9714924","article-title":"Crystal structure of human arylsulfatase A: the aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis","volume":"37","author":"Lukatela","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.neurot.2024.e00443_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.576221","article-title":"Metachromatic leukodystrophy: diagnosis, modeling, and treatment approaches","volume":"7","author":"Shaimardanova","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.neurot.2024.e00443_bib54","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0140-6736(85)90402-7","article-title":"Bone-marrow transplantation for metachromatic leucodystrophy","volume":"2","author":"Bayever","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2024.e00443_bib55","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/bmt.2014.93","article-title":"Hematopoietic SCT: a useful treatment for late metachromatic leukodystrophy","volume":"49","author":"Solders","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.neurot.2024.e00443_bib56","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1172\/JCI200419205","article-title":"Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells","volume":"113","author":"Biffi","year":"2004","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.neurot.2024.e00443_bib57","doi-asserted-by":"crossref","first-page":"14821","DOI":"10.1073\/pnas.93.25.14821","article-title":"Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy","volume":"93","author":"Hess","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurot.2024.e00443_bib58","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1172\/JCI28873","article-title":"Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice","volume":"116","author":"Biffi","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.neurot.2024.e00443_bib59","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.162.3853.570","article-title":"Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts","volume":"162","author":"Fratantoni","year":"1968","journal-title":"Science"},{"key":"10.1016\/j.neurot.2024.e00443_bib60","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.neurot.2024.e00443_bib61","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2024.e00443_bib62","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"issue":"S1","key":"10.1016\/j.neurot.2024.e00443_bib63","first-page":"100882","article-title":"Atidarsagene autotemcel (hematopoietic stem cell-gene therapy) preserves cognitive and motor development in metachromatic leukodystrophy with up to 12 years follow-up [ACMG abstract 005]","volume":"2","author":"Fumagalli","year":"2024","journal-title":"GIM Open"},{"key":"10.1016\/j.neurot.2024.e00443_bib64","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13023-019-1060-2","article-title":"Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers","volume":"14","author":"Harrington","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.neurot.2024.e00443_bib65","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaneurol.2016.2067","article-title":"Long-term outcome of allogeneic hematopoietic stem cell transplantation in patients with juvenile metachromatic leukodystrophy compared with nontransplanted control patients","volume":"73","author":"Groeschel","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib66","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/acn3.51796","article-title":"Neurodegenerative disease after hematopoietic stem cell transplantation in metachromatic leukodystrophy","volume":"10","author":"Al-Saady","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib67","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/85454","article-title":"In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice","volume":"7","author":"Consiglio","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2024.e00443_bib68","first-page":"557","article-title":"Compound heterozygosity for metachromatic leukodystrophy and arylsulfatase A pseudodeficiency alleles is not associated with progressive neurological disease","volume":"52","author":"Penzien","year":"1993","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.neurot.2024.e00443_bib69","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/BF00219337","article-title":"Quantitative correlation between the residual activity of \u03b2-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease","volume":"88","author":"Leinekugel","year":"1992","journal-title":"Hum Genet"},{"key":"10.1016\/j.neurot.2024.e00443_bib70","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/hmg\/ddi425","article-title":"Intracerebral adeno-associated virus-mediated gene transfer in rapidly progressive forms of metachromatic leukodystrophy","volume":"15","author":"Sevin","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00443_bib71","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.gt.3302883","article-title":"Partial cure of established disease in an animal model of metachromatic leukodystrophy after intracerebral adeno-associated virus-mediated gene transfer","volume":"14","author":"Sevin","year":"2007","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib72","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/humc.2014.139","article-title":"Intracerebral gene therapy using AAVrh.10-hARSA recombinant vector to treat patients with early-onset forms of metachromatic leukodystrophy: preclinical feasibility and safety assessments in nonhuman primates","volume":"26","author":"Zerah","year":"2015","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00443_bib73","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/j.ymgme.2017.12.352","article-title":"Intracerebral gene therapy in children with metachromatic leukodystrophy: results of a phase I\/II trial","volume":"123","author":"Sevin","year":"2018","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.neurot.2024.e00443_bib74","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3171\/2021.2.PEDS201006","article-title":"Normal childhood brain growth and a universal sex and anthropomorphic relationship to cerebrospinal fluid","volume":"28","author":"Peterson","year":"2021","journal-title":"J\u00a0Neurosurg Pediatr"},{"key":"10.1016\/j.neurot.2024.e00443_bib75","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/hum.2022.163","article-title":"Biodistribution of adeno-associated virus gene therapy following cerebrospinal fluid-directed administration","volume":"34","author":"Chen","year":"2023","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib76","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/hum.2020.269","article-title":"Safety of direct intraparenchymal AAVrh.10-mediated central nervous system gene therapy for metachromatic leukodystrophy","volume":"32","author":"Rosenberg","year":"2021","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib77","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/glia.23598","article-title":"Microglia damage precedes major myelin breakdown in X-linked adrenoleukodystrophy and metachromatic leukodystrophy","volume":"67","author":"Bergner","year":"2019","journal-title":"Glia"},{"key":"10.1016\/j.neurot.2024.e00443_bib78","doi-asserted-by":"crossref","first-page":"9945","DOI":"10.1523\/JNEUROSCI.1802-11.2011","article-title":"Bone marrow transplantation augments the effect of brain- and spinal cord-directed adeno-associated virus 2\/5 gene therapy by altering inflammation in the murine model of globoid-cell leukodystrophy","volume":"31","author":"Reddy","year":"2011","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.neurot.2024.e00443_bib79","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/jdn.10003","article-title":"X-linked adrenoleukodystrophy: pathology, pathophysiology, diagnostic testing, newborn screening and therapies","volume":"80","author":"Turk","year":"2020","journal-title":"Int J Dev Neurosci"},{"key":"10.1016\/j.neurot.2024.e00443_bib80","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/ncpneuro0421","article-title":"X-linked adrenoleukodystrophy","volume":"3","author":"Moser","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib81","series-title":"Encyclopedia of the neurological sciences","first-page":"65","article-title":"Adrenoleukodystrophy","author":"Percy","year":"2014"},{"key":"10.1016\/j.neurot.2024.e00443_bib82","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.21391","article-title":"Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy?","volume":"63","author":"Eichler","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib83","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1525-0016(03)00002-9","article-title":"Transduced CD34+ cells from adrenoleukodystrophy patients with HIV-derived vector mediate long-term engraftment of NOD\/SCID mice","volume":"7","author":"Benhamida","year":"2003","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib84","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1073\/pnas.0306431101","article-title":"Human CD34+ cells differentiate into microglia and express recombinant therapeutic protein","volume":"101","author":"Asheuer","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurot.2024.e00443_bib85","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bbmt.2018.09.036","article-title":"Survival and functional outcomes in boys with cerebral adrenoleukodystrophy with and without hematopoietic stem cell transplantation","volume":"25","author":"Raymond","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.neurot.2024.e00443_bib86","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/bloodadvances.2021005294","article-title":"Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy","volume":"6","author":"Chiesa","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.neurot.2024.e00443_bib87","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.neurot.2024.e00443_bib88","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1089\/hum.2021.053","article-title":"Long-term follow-up of hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"32","author":"Bougn\u00e8res","year":"2021","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib89","first-page":"1761","article-title":"Adrenoleukodystrophy: a scoring method for brain MR observations","volume":"15","author":"Loes","year":"1994","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.neurot.2024.e00443_bib90","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-2000-9236","article-title":"X-Linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients","volume":"31","author":"Moser","year":"2000","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.neurot.2024.e00443_bib91","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00443_bib92","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.96.15_supplement.2064","article-title":"Disease stabilization following treatment with elivaldogene autotemcel (eli-cel, lenti-D) gene therapy for the treatment of cerebral adrenoleukodystrophy: interim results from phase 2\/3 (ALD-102) and phase 3 (ALD-104) studies (2064)","volume":"96","author":"Eichler","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00443_bib93","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/1531-8249(199901)45:1<100::AID-ART16>3.0.CO;2-U","article-title":"Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls","volume":"45","author":"Moser","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib94","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2878","article-title":"Self-reported quality of life in symptomatic and asymptomatic women with X-linked adrenoleukodystrophy","volume":"13","author":"Sch\u00e4fer","year":"2023","journal-title":"Brain Behav"},{"key":"10.1016\/j.neurot.2024.e00443_bib95","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jnen\/60.5.493","article-title":"The dorsal root ganglia in adrenomyeloneuropathy: neuronal atrophy and abnormal mitochondria","volume":"60","author":"Powers","year":"2001","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib96","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ana.26849","article-title":"Role of basal forebrain neurons in adrenomyeloneuropathy in mice and humans","volume":"95","author":"Gong","year":"2024","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib97","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.omtm.2020.04.001","article-title":"Intra-CSF AAV9 and AAVrh10 administration in nonhuman primates: promising routes and vectors for which neurological diseases?","volume":"17","author":"Bey","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00443_bib98","unstructured":"Anderson D, Maguire C, Ng C, Gong Y, Eichler F, Fourcase S, et\u00a0al. Selection of clinical doses for SBT101, an AAV9-hABCD1 vector for the treatment of adrenomyeloneuropathy [abstract]. Mov Disord n.d.;37.."},{"key":"10.1016\/j.neurot.2024.e00443_bib99","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1089\/hum.2020.217","article-title":"Re: \u201cmoving forward after two deaths in a gene therapy trial of myotubular myopathy\u201d by wilson and flotte","volume":"31","author":"Shieh","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.135841","article-title":"Krabbe disease: new hope for an old disease","volume":"752","author":"Bradbury","year":"2021","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.neurot.2024.e00443_bib101","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1194\/jlr.M039610","article-title":"Psychosine, the cytotoxic sphingolipid that accumulates in globoid cell leukodystrophy, alters membrane architecture","volume":"54","author":"Hawkins-Salsbury","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.neurot.2024.e00443_bib102","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1046\/j.1471-4159.2003.01941.x","article-title":"Molecular mechanism of psychosine-induced cell death in human oligodendrocyte cell line","volume":"86","author":"Haq","year":"2003","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.neurot.2024.e00443_bib103","doi-asserted-by":"crossref","first-page":"20097","DOI":"10.1073\/pnas.1912108116","article-title":"Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target","volume":"116","author":"Li","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurot.2024.e00443_bib104","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.nbd.2019.05.011","article-title":"Dysregulated autophagy as a new aspect of the molecular pathogenesis of Krabbe disease","volume":"129","author":"Del Grosso","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2024.e00443_bib105","doi-asserted-by":"crossref","DOI":"10.1177\/17590914221087817","article-title":"The pathogenic sphingolipid psychosine is secreted in extracellular vesicles in the brain of a mouse model of krabbe disease","volume":"14","author":"Reiter","year":"2022","journal-title":"ASN Neuro"},{"key":"10.1016\/j.neurot.2024.e00443_bib106","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/path.4328","article-title":"Neuronal inclusions of \u03b1-synuclein contribute to the pathogenesis of Krabbe disease","volume":"232","author":"Smith","year":"2014","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.neurot.2024.e00443_bib107","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/brain\/awac002","article-title":"Prion-like \u03b1-synuclein pathology in the brain of infants with Krabbe disease","volume":"145","author":"Hatton","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2024.e00443_bib108","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41436-019-0480-7","article-title":"Clinical characteristics of 248 patients with Krabbe disease: quantitative natural history modeling based on published cases","volume":"21","author":"Komatsuzaki","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.neurot.2024.e00443_bib109","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1212\/01.wnl.0000230153.34613.84","article-title":"Peripheral neuropathy in Krabbe disease: electrodiagnostic findings","volume":"67","author":"Siddiqi","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00443_bib110","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/mt.2011.98","article-title":"Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib111","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ymgme.2014.12.300","article-title":"Intravenous injection of AAVrh10-GALC after the neonatal period in twitcher mice results in significant expression in the central and peripheral nervous systems and improvement of clinical features","volume":"114","author":"Rafi","year":"2015","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.neurot.2024.e00443_bib112","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ymthe.2005.04.019","article-title":"AAV2\/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2","volume":"12","author":"Lin","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib113","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1523\/JNEUROSCI.4199-14.2015","article-title":"Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy","volume":"35","author":"Hawkins-Salsbury","year":"2015","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.neurot.2024.e00443_bib114","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ymthe.2020.12.031","article-title":"Enhanced efficacy and increased long-term toxicity of CNS-directed, AAV-based combination therapy for krabbe disease","volume":"29","author":"Li","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.neuron.2020.03.031","article-title":"Macrophages expressing GALC improve peripheral krabbe disease by a mechanism independent of cross-correction","volume":"107","author":"Weinstock","year":"2020","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2024.e00443_bib116","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.mt.6300026","article-title":"Central nervous system-directed AAV2\/5-mediated gene therapy synergizes with bone marrow transplantation in the murine model of globoid-cell leukodystrophy","volume":"15","author":"Lin","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib117","doi-asserted-by":"crossref","first-page":"135","DOI":"10.34172\/bi.2021.21","article-title":"Can early treatment of twitcher mice with high dose AAVrh10-GALC eliminate the need for BMT?","volume":"11","author":"Rafi","year":"2021","journal-title":"Bioimpacts"},{"key":"10.1016\/j.neurot.2024.e00443_bib118","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ymthe.2023.11.014","article-title":"Combination HSCT and intravenous AAV-mediated gene therapy in a canine model proves pivotal for translation of Krabbe disease therapy","volume":"32","author":"Bradbury","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib119","article-title":"P014: first-in-human phase 1\/2 trial of intravenous FBX-101 with cord blood transplantation increases GALC, brain and motor development in infantile Krabbe","volume":"1","author":"Escolar","year":"2023","journal-title":"Genet Med"},{"key":"10.1016\/j.neurot.2024.e00443_bib120","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.omtm.2020.04.012","article-title":"Translational feasibility of lumbar puncture for intrathecal AAV administration","volume":"17","author":"Hinderer","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00443_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.888231","article-title":"Improved brain pathology and progressive peripheral neuropathy in a 15 Year old survivor of infantile krabbe disease treated with umbilical cord transplantation","volume":"15","author":"Kofler","year":"2022","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.neurot.2024.e00443_bib122","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1046\/j.1471-4159.2001.00456.x","article-title":"Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase","volume":"78","author":"Chakraborty","year":"2001","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.neurot.2024.e00443_bib123","doi-asserted-by":"crossref","first-page":"11537","DOI":"10.1523\/JNEUROSCI.1490-08.2008","article-title":"Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS","volume":"28","author":"Traka","year":"2008","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.neurot.2024.e00443_bib124","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s13023-020-01659-3","article-title":"The natural history of Canavan disease: 23 new cases and comparison with patients from literature","volume":"16","author":"Bley","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.neurot.2024.e00443_bib125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0887-8994(97)00185-9","article-title":"The clinical course of Canavan disease","volume":"18","author":"Traeger","year":"1998","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib126","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/1531-8249(200007)48:1<27::AID-ANA6>3.0.CO;2-6","article-title":"Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease","volume":"48","author":"Leone","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib127","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003454","article-title":"Long-term follow-up after gene therapy for canavan disease","volume":"4","author":"Leone","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurot.2024.e00443_bib128","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/gt.2016.62","article-title":"Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism","volume":"23","author":"Powell","year":"2016","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib129","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.omtm.2021.01.009","article-title":"Preclinical biodistribution, tropism, and efficacy of oligotropic AAV\/Olig001 in a mouse model of congenital white matter disease","volume":"20","author":"Francis","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00443_bib130","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S1525-0016(03)00066-2","article-title":"Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease","volume":"7","author":"Matalon","year":"2003","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib131","author":"Eichler","year":"2023","journal-title":"Initial biomarker and clinical findings from the CANaspire canavan disease gene therapy trial: exploration of connections between NAA and disease severity"},{"key":"10.1016\/j.neurot.2024.e00443_bib132","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00439-016-1659-5","article-title":"A\u00a0review of gigaxonin mutations in giant axonal neuropathy (GAN) and cancer","volume":"135","author":"Kang","year":"2016","journal-title":"Hum Genet"},{"key":"10.1016\/j.neurot.2024.e00443_bib133","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127751","article-title":"Gigaxonin glycosylation regulates intermediate filament turnover and may impact giant axonal neuropathy etiology or treatment","volume":"5","author":"Chen","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.neurot.2024.e00443_bib134","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1093\/brain\/awab179","article-title":"Giant axonal neuropathy: cross-sectional analysis of a large natural history cohort","volume":"144","author":"Bharucha-Goebel","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2024.e00443_bib135","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1136\/jnnp.2003.035162","article-title":"Giant axonal neuropathy: clinical and genetic study in six cases","volume":"76","author":"Demir","year":"2005","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2024.e00443_bib136","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1212\/01.WNL.0000101676.41505.A7","article-title":"Clinical and molecular findings in patients with giant axonal neuropathy (GAN)","volume":"62","author":"Bruno","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00443_bib137","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1055\/s-2008-1059670","article-title":"Giant axonal neuropathy: report of two siblings with endocrinological and histological studies","volume":"12","author":"Takebe","year":"1981","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.neurot.2024.e00443_bib138","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/jnnp.46.6.551","article-title":"Giant axonal neuropathy: normal protein composition of neurofilaments","volume":"46","author":"Ionasescu","year":"1983","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2024.e00443_bib139","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0387-7604(98)00056-4","article-title":"A\u00a0case of giant axonal neuropathy showing focal aggregation and hypophosphorylation of intermediate filaments","volume":"20","author":"Mohri","year":"1998","journal-title":"Brain Dev"},{"key":"10.1016\/j.neurot.2024.e00443_bib140","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/088307389000500316","article-title":"Giant axonal neuropathy: clinical, electrophysiologic, and neuropathologic features in two siblings","volume":"5","author":"Kumar","year":"1990","journal-title":"J\u00a0Child Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib141","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1136\/jnnp.2007.118968","article-title":"New mutations, genotype phenotype studies and manifesting carriers in giant axonal neuropathy","volume":"78","author":"Houlden","year":"2007","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2024.e00443_bib142","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/088307389501000322","article-title":"Giant axonal neuropathy in a child with insulin-dependent diabetes mellitus","volume":"10","author":"Hoffman","year":"1995","journal-title":"J\u00a0Child Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib143","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00018-007-6396-4","article-title":"Giant axonal neuropathy","volume":"64","author":"Yang","year":"2007","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.neurot.2024.e00443_bib144","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nmd.2013.06.007","article-title":"The absence of curly hair is associated with a milder phenotype in Giant Axonal Neuropathy","volume":"24","author":"Roth","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.neurot.2024.e00443_bib145","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1089\/hum.2012.107","article-title":"Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy","volume":"24","author":"Mussche","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib146","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1172\/JCI66387","article-title":"Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation","volume":"123","author":"Mahammad","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.neurot.2024.e00443_bib147","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/hmg\/ddu556","article-title":"Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin","volume":"24","author":"Johnson-Kerner","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00443_bib148","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/hmg\/ddl069","article-title":"Gene targeting of GAN in mouse causes a toxic accumulation of microtubule-associated protein 8 and impaired retrograde axonal transport","volume":"15","author":"Ding","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00443_bib149","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1471-4159.2008.05601.x","article-title":"Modest loss of peripheral axons, muscle atrophy and formation of brain inclusions in mice with targeted deletion of gigaxonin exon 1","volume":"107","author":"Dequen","year":"2008","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.neurot.2024.e00443_bib150","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/hmg\/ddp044","article-title":"Gigaxonin controls vimentin organization through a tubulin chaperone-independent pathway","volume":"18","author":"Cleveland","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00443_bib151","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa2307952","article-title":"Intrathecal gene therapy for giant axonal neuropathy","volume":"390","author":"Bharucha-Goebel","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00443_bib152","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.3390\/ijms21176213","article-title":"GM2 gangliosidoses: clinical features, pathophysiological aspects, and current therapies","volume":"21","author":"Leal","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurot.2024.e00443_bib153","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF00691417","article-title":"The white matter in GM2 gangliosidosis","volume":"24","author":"Haberland","year":"1973","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2024.e00443_bib154","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bbamcr.2018.10.014","article-title":"Neurite atrophy and apoptosis mediated by PERK signaling after accumulation of GM2-ganglioside","volume":"1866","author":"Virgolini","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10.1016\/j.neurot.2024.e00443_bib155","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/sj.cdd.4401834","article-title":"Gangliosides as apoptotic signals in ER stress response","volume":"13","author":"d'Azzo","year":"2006","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.neurot.2024.e00443_bib156","doi-asserted-by":"crossref","first-page":"e1233","DOI":"10.1542\/peds.2011-0078","article-title":"Natural history of infantile G(M2) gangliosidosis","volume":"128","author":"Bley","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.neurot.2024.e00443_bib157","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1469-8749.2011.04160.x","article-title":"GM2 gangliosidosis in a UK study of children with progressive neurodegeneration: 73 cases reviewed","volume":"54","author":"Smith","year":"2012","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib158","doi-asserted-by":"crossref","first-page":"e1550","DOI":"10.1542\/peds.2006-0588","article-title":"The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported","volume":"118","author":"Maegawa","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.neurot.2024.e00443_bib159","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/01.GIM.0000154300.84107.75","article-title":"Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients","volume":"7","author":"Neudorfer","year":"2005","journal-title":"Genet Med"},{"key":"10.1016\/j.neurot.2024.e00443_bib160","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/hmg\/8.5.831","article-title":"Adenoviral gene therapy of the Tay-Sachs disease in hexosaminidase A-deficient knock-out mice","volume":"8","author":"Guidotti","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00443_bib161","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.nbd.2005.04.017","article-title":"Bicistronic lentiviral vector corrects beta-hexosaminidase deficiency in transduced and cross-corrected human Sandhoff fibroblasts","volume":"20","author":"Arfi","year":"2005","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2024.e00443_bib162","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1248\/bpb.29.1564","article-title":"Inefficiency in GM2 ganglioside elimination by human lysosomal beta-hexosaminidase beta-subunit gene transfer to fibroblastic cell line derived from Sandhoff disease model mice","volume":"29","author":"Itakura","year":"2006","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.neurot.2024.e00443_bib163","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ng1095-170","article-title":"Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism","volume":"11","author":"Sango","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurot.2024.e00443_bib164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/hmg\/5.1.1","article-title":"Dramatically different phenotypes in mouse models of human tay-sachs and sandhoff diseases","volume":"5","author":"Phaneuf","year":"1996","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00443_bib165","doi-asserted-by":"crossref","first-page":"10373","DOI":"10.1073\/pnas.0603765103","article-title":"Effective gene therapy in an authentic model of Tay-Sachs-related diseases","volume":"103","author":"Cach\u00f3n-Gonz\u00e1lez","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.neurot.2024.e00443_bib166","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/mt.2012.44","article-title":"Gene transfer corrects acute GM2 gangliosidosis\u2014potential therapeutic contribution of perivascular enzyme flow","volume":"20","author":"Cach\u00f3n-Gonz\u00e1lez","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib167","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1089\/10430340460745793","article-title":"Basic fibroblast growth factor enhances transduction, distribution, and axonal transport of adeno-associated virus type 2 vector in rat brain","volume":"15","author":"Hadaczek","year":"2004","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib168","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1126\/science.1086137","article-title":"Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model","volume":"301","author":"Kaspar","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.neurot.2024.e00443_bib169","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/mt.2013.86","article-title":"Therapeutic response in feline sandhoff disease despite immunity to intracranial gene therapy","volume":"21","author":"Bradbury","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib170","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jsb.2015.08.017","article-title":"Structure of neurotropic adeno-associated virus AAVrh.8","volume":"192","author":"Halder","year":"2015","journal-title":"J\u00a0Struct Biol"},{"key":"10.1016\/j.neurot.2024.e00443_bib171","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/gt.2014.108","article-title":"Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease","volume":"22","author":"McCurdy","year":"2015","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib172","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.expneurol.2014.09.020","article-title":"Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease","volume":"263","author":"Bradbury","year":"2015","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib173","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ymgme.2010.08.006","article-title":"Tay-Sachs disease in Jacob sheep","volume":"101","author":"Torres","year":"2010","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.neurot.2024.e00443_bib174","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymgme.2021.08.009","article-title":"Natural history of tay-sachs disease in sheep","volume":"134","author":"Story","year":"2021","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.neurot.2024.e00443_bib175","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S1525-0016(16)34375-1","article-title":"Amelioration of neurologic disease after AAV-gene therapy in a sheep model of tay-sachs disease","volume":"21","author":"Gray-Edwards","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib176","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1089\/hum.2017.163","article-title":"Adeno-associated virus gene therapy in a sheep model of tay\u2013sachs disease","volume":"29","author":"Gray-Edwards","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib177","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41591-021-01664-4","article-title":"AAV gene therapy for Tay-Sachs disease","volume":"28","author":"Flotte","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2024.e00443_bib178","first-page":"958","article-title":"Neuropathology for the neuroradiologist: Rosenthal fibers","volume":"27","author":"Wippold","year":"2006","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.neurot.2024.e00443_bib179","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40478-017-0425-9","article-title":"The origin of Rosenthal fibers and their contributions to astrocyte pathology in Alexander disease","volume":"5","author":"Sosunov","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neurot.2024.e00443_bib180","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1074\/jbc.M116.772020","article-title":"Glial fibrillary acidic protein exhibits altered turnover kinetics in a mouse model of Alexander disease","volume":"292","author":"Moody","year":"2017","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.neurot.2024.e00443_bib181","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/B978-0-444-64076-5.00044-2","article-title":"Alexander disease","volume":"148","author":"Messing","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib182","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg4711","article-title":"Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment","volume":"13","author":"Hagemann","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurot.2024.e00443_bib183","first-page":"391","article-title":"Fatal encephalopathy with astrocyte inclusions in GFAP transgenic mice","volume":"152","author":"Messing","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1016\/j.neurot.2024.e00443_bib184","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00401-015-1469-1","article-title":"Astrocyte pathology in Alexander disease causes a marked inflammatory environment","volume":"130","author":"Olabarria","year":"2015","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2024.e00443_bib185","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/NEN.0b013e3181d3cb52","article-title":"Alexander disease mutant glial fibrillary acidic protein compromises glutamate transport in astrocytes","volume":"69","author":"Tian","year":"2010","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib186","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1523\/JNEUROSCI.3410-10.2011","article-title":"Protein misfolding and oxidative stress promote glial-mediated neurodegeneration in an Alexander disease model","volume":"31","author":"Wang","year":"2011","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.neurot.2024.e00443_bib187","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1212\/WNL.0b013e3182309f72","article-title":"GFAP mutations, age at onset, and clinical subtypes in Alexander disease","volume":"77","author":"Prust","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00443_bib188","series-title":"Alexander disease. StatPearls, treasure island (FL)","author":"Kuhn","year":"2024"},{"key":"10.1016\/j.neurot.2024.e00443_bib189","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3390\/pharmaceutics14081708","article-title":"Towards personalized allele-specific antisense oligonucleotide therapies for toxic gain-of-function neurodegenerative diseases","volume":"14","author":"Helm","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neurot.2024.e00443_bib190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ana.25118","article-title":"Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease","volume":"83","author":"Hagemann","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2024.e00443_bib191","doi-asserted-by":"crossref","first-page":"11162","DOI":"10.1523\/JNEUROSCI.3260-06.2006","article-title":"Alexander disease-associated glial fibrillary acidic protein mutations in mice induce Rosenthal fiber formation and a white matter stress response","volume":"26","author":"Hagemann","year":"2006","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.neurot.2024.e00443_bib192","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/nar\/gkaa1235","article-title":"The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration","volume":"49","author":"Jafar-nejad","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.neurot.2024.e00443_bib193","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.molmed.2024.03.005","article-title":"Pelizaeus-Merzbacher disease: on the cusp of myelin medicine","volume":"30","author":"Elitt","year":"2024","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.neurot.2024.e00443_bib194","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fmolb.2017.00007","article-title":"Cellular pathology of pelizaeus-merzbacher disease involving chaperones associated with endoplasmic reticulum stress","volume":"4","author":"Inoue","year":"2017","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.neurot.2024.e00443_bib195","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0896-6273(02)01045-0","article-title":"The unfolded protein response modulates disease severity in Pelizaeus-Merzbacher disease","volume":"36","author":"Southwood","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2024.e00443_bib196","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1083\/jcb.140.4.925","article-title":"Disrupted proteolipid protein trafficking results in oligodendrocyte apoptosis in an animal model of Pelizaeus-Merzbacher disease","volume":"140","author":"Gow","year":"1998","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.neurot.2024.e00443_bib197","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-981-32-9636-7_13","article-title":"Pelizaeus-merzbacher disease: molecular and cellular pathologies and associated phenotypes","volume":"1190","author":"Inoue","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.neurot.2024.e00443_bib198","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-6-40","article-title":"Molecular genetic analysis of the PLP1 gene in 38 families with PLP1-related disorders: identification and functional characterization of 11 novel PLP1 mutations","volume":"6","author":"Grossi","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.neurot.2024.e00443_bib199","first-page":"322","article-title":"Jimpy, a new totally sex-linked gene in the house mouse","volume":"86","author":"Phillips","year":"1954","journal-title":"Z\u00a0Vererbungslehre"},{"key":"10.1016\/j.neurot.2024.e00443_bib200","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.144.3616.309","article-title":"Mutant mice (quaking and jimpy) with deficient myelination in the central nervous system","volume":"144","author":"Sidman","year":"1964","journal-title":"Science"},{"key":"10.1016\/j.neurot.2024.e00443_bib201","doi-asserted-by":"crossref","first-page":"9264","DOI":"10.1073\/pnas.83.23.9264","article-title":"Jimpy mutant mouse: a 74-base deletion in the mRNA for myelin proteolipid protein and evidence for a primary defect in RNA splicing","volume":"83","author":"Nave","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurot.2024.e00443_bib202","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41586-020-2494-3","article-title":"Suppression of proteolipid protein rescues Pelizaeus-Merzbacher disease","volume":"585","author":"Elitt","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2024.e00443_bib203","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJM200301163480314","article-title":"A\u00a0serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency","volume":"348","author":"Hacein-Bey-Abina","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00443_bib204","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.neurot.2024.e00443_bib205","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.neurot.2024.e00443_bib206","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/14712598.2022.2124857","article-title":"Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy","volume":"22","author":"Gupta","year":"2022","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib207","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41408-021-00457-9","article-title":"EVI1 dysregulation: impact on biology and therapy of myeloid malignancies","volume":"11","author":"Birdwell","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.neurot.2024.e00443_bib208","doi-asserted-by":"crossref","first-page":"e959","DOI":"10.1097\/HS9.0000000000000959","article-title":"EVI1-mediated programming of normal and malignant hematopoiesis","volume":"7","author":"Lux","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.neurot.2024.e00443_bib209","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/leu.2012.355","article-title":"Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cells","volume":"27","author":"Kustikova","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.neurot.2024.e00443_bib210","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1182\/blood-2010-09-306761","article-title":"Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection","volume":"117","author":"Biffi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.neurot.2024.e00443_bib211","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209034","article-title":"Improved multilineage human hematopoietic reconstitution and function in NSGS mice","volume":"13","author":"Wunderlich","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2024.e00443_bib212","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41409-022-01567-z","article-title":"Clonal evolution in patients developing therapy-related myeloid neoplasms following autologous stem cell transplantation","volume":"57","author":"Soerensen","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.neurot.2024.e00443_bib213","doi-asserted-by":"crossref","first-page":"9451","DOI":"10.1128\/JVI.74.20.9451-9463.2000","article-title":"Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo","volume":"74","author":"Nakai","year":"2000","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.neurot.2024.e00443_bib214","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1743-422X-2-43","article-title":"Adeno-associated virus: from defective virus to effective vector","volume":"2","author":"Gon\u00e7alves","year":"2005","journal-title":"Virol J"},{"key":"10.1016\/j.neurot.2024.e00443_bib215","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/ng1179","article-title":"AAV serotype 2 vectors preferentially integrate into active genes in mice","volume":"34","author":"Nakai","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurot.2024.e00443_bib216","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/hum.2017.009","article-title":"Recombinant adeno-associated viral integration and genotoxicity: insights from animal models","volume":"28","author":"Chandler","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib217","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A\u00a0long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.neurot.2024.e00443_bib218","article-title":"Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration","author":"Greig","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.neurot.2024.e00443_bib219","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurot.2024.e00443_bib220","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/gutjnl-2019-318281","article-title":"Adeno-associated virus in the liver: natural history and consequences in tumour development","volume":"69","author":"La Bella","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.neurot.2024.e00443_bib221","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1126\/science.1142658","article-title":"AAV vector integration sites in mouse hepatocellular carcinoma","volume":"317","author":"Donsante","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.neurot.2024.e00443_bib222","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the state of the science for adeno-associated virus integration: an integrated perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib223","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1182\/bloodadvances.2023009876","article-title":"Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B","volume":"7","author":"Schmidt","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.neurot.2024.e00443_bib224","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00443_bib225","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.950651","article-title":"Drug development progress in duchenne muscular dystrophy","volume":"13","author":"Deng","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.neurot.2024.e00443_bib226","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.ymthe.2020.07.009","article-title":"Broader implications of progressive liver dysfunction and lethal sepsis in two boys following systemic high-dose AAV","volume":"28","author":"Morales","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib227","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.ymthe.2024.02.002","article-title":"High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury","volume":"32","author":"Hordeaux","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib228","doi-asserted-by":"crossref","DOI":"10.1016\/j.ekir.2024.04.024","article-title":"Thrombotic microangiopathy as an emerging complication of viral vector\u2013based gene therapy","author":"Schwotzer","year":"2024","journal-title":"Kidney International Reports"},{"key":"10.1016\/j.neurot.2024.e00443_bib229","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res"},{"key":"10.1016\/j.neurot.2024.e00443_bib230","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.675897","article-title":"Challenges posed by immune responses to AAV vectors: addressing root causes","volume":"12","author":"Hamilton","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2024.e00443_bib231","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/JVI.01990-07","article-title":"Complement is an essential component of the immune response to adeno-associated virus vectors","volume":"82","author":"Zaiss","year":"2008","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.neurot.2024.e00443_bib232","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.564647","article-title":"Efficacy and safety of eculizumab in the treatment of transplant-associated thrombotic microangiopathy: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2024.e00443_bib233","first-page":"31","article-title":"Systemic administration of novel engineered AAV capsids facilitates enhanced transgene expression in the macaque CNS","volume":"4","author":"Stanton","year":"2023","journal-title":"M\u00e9d"},{"key":"10.1016\/j.neurot.2024.e00443_bib234","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/s42003-022-04200-3","article-title":"Development of microglia-targeting adeno-associated viral vectors as tools to study microglial behavior in vivo","volume":"5","author":"Okada","year":"2022","journal-title":"Commun Biol"},{"key":"10.1016\/j.neurot.2024.e00443_bib235","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2302997120","article-title":"Targeted evolution of adeno-associated virus capsids for systemic transgene delivery to microglia and tissue-resident macrophages","volume":"120","author":"Young","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurot.2024.e00443_bib236","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41592-022-01547-7","article-title":"Directed evolution of adeno-associated virus for efficient gene delivery to microglia","volume":"19","author":"Lin","year":"2022","journal-title":"Nat Methods"},{"key":"10.1016\/j.neurot.2024.e00443_bib237","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/mt.2011.22","article-title":"Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer","volume":"19","author":"Pulicherla","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib238","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1089\/hum.2016.130","article-title":"Systemic and persistent muscle gene expression in rhesus monkeys with a liver de-targeted adeno-associated virus vector","volume":"28","author":"Tarantal","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00443_bib239","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.3390\/ijms21103433","article-title":"Evading the AAV immune response in mucopolysaccharidoses","volume":"21","author":"Piechnik","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurot.2024.e00443_bib240","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.tibtech.2022.11.006","article-title":"Evading and overcoming AAV neutralization in gene therapy","volume":"41","author":"Earley","year":"2023","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.neurot.2024.e00443_bib241","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41392-024-01750-2","article-title":"Precise genome-editing in human diseases: mechanisms, strategies and applications","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Targeted Ther"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924001302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924001302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T21:12:38Z","timestamp":1727125958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747924001302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":241,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1878747924001302"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00443","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00443"}}